Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAmati Aim Vct Regulatory News (AMAT)

  • There is currently no data for AMAT

Strategic Review

14 Mar 2024 07:00

RNS Number : 7782G
Amati AIM VCT PLC
14 March 2024
Β 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICITON WHERE TO DO SO WOULD COSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THE JURISDICITON.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATON FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. ON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

For immediate release

14 March 2024

Amati AIM VCT plc

Β 

Strategic review

Β 

The Board of Amati AIM VCT plc (the "Company") confirms that it has, in conjunction with the Company's investment manager, Amati Global Investors Limited (the "Investment Manager"), been considering the Company's strategic optionsΒ in the light of ongoingΒ challenges in the AIM market and the resultant performance issues faced by the Company. As part of this review, the Board intends to consider whether the Company's investment strategy should be expanded to facilitate investment in a broader range of securities while continuing to comply with the rules applicable to VCTs.Β 

Β 

The Board also notes the recent announcement of a recommended offer (the "Offer") for Mattioli Woods plc by Tiger Bidco Limited (owned by funds managed by Pollen Street Capital Limited). Mattioli Woods plc currently owns 49% of the issued share capital of the Investment Manager. The ongoing review of strategic options will take into account any possible impact of the Offer on the CompanyΒ and the management of its investment portfolio.

Β 

Further details of the strategic review will be included in the Company's annual report and accounts which are expected to be published shortly.

Β 

Enquiries:

Β 

Fiona Wollocombe, Chair

Amati AIM VCT plc

Email: info@amatiglobal.com

Β 

Douglas Armstrong

Dickson Minto Advisers

Financial Adviser to the Company

Telephone: 020 7649 6823

Β 

Important Information

This announcement is released by the Company and the information contained within this announcement is deemed by the Company to constitute inside information for the purposes of Article 7 of the UK version of the EU Market Abuse Regulation (Regulation (EU) No.596/2014) which forms part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, such information is now considered to be in the public domain.

Legal Entity Identifier (LEI): 213800HAEDBBK9RWCD25

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
UPDSFMFUDELSEID
Date   Source Headline
24th Jun 20242:08 pmRNSNet Asset Value(s)
21st Jun 20244:17 pmRNSTransaction in Own Shares
14th Jun 20244:47 pmRNSNet Asset Value(s)
13th Jun 20244:20 pmRNSResult of AGM
10th Jun 202410:01 amRNSNet Asset Value(s)
6th Jun 20243:08 pmRNSTransaction in Own Shares
3rd Jun 20244:21 pmRNSNet Asset Value(s)
3rd Jun 20243:20 pmRNSTotal Voting Rights
28th May 20241:59 pmRNSNet Asset Value(s)
23rd May 20245:10 pmRNSTransaction in Own Shares
20th May 20245:06 pmRNSTransaction in Own Shares
20th May 20243:46 pmRNSTransaction in Own Shares
17th May 20244:27 pmRNSNet Asset Value(s)
16th May 202412:15 pmRNSTransaction in Own Shares
16th May 20247:00 amRNSTransaction in Own Shares
13th May 202410:28 amRNSNet Asset Value(s)
9th May 20243:41 pmRNSStrategic Review and Special Dividend
2nd May 202410:38 amRNSNet Asset Value(s)
1st May 20243:59 pmRNSTotal Voting Rights
30th Apr 20245:03 pmRNSTransaction in Own Shares
26th Apr 20244:29 pmRNSNet Asset Value(s)
22nd Apr 202411:21 amRNSNet Asset Value(s)
15th Apr 202410:36 amRNSNet Asset Value(s)
12th Apr 20247:00 amRNSAnnual Financial Report
8th Apr 202411:58 amRNSNet Asset Value(s)
3rd Apr 20241:04 pmRNSNet Asset Value(s)
3rd Apr 202412:15 pmRNSTransaction in Own Shares
2nd Apr 202411:06 amRNSTotal Voting Rights
25th Mar 20242:26 pmRNSTransaction in Own Shares
25th Mar 202412:39 pmRNSNet Asset Value(s)
18th Mar 20241:55 pmRNSNet Asset Value(s)
15th Mar 20243:00 pmRNSTransaction in Own Shares
14th Mar 20245:11 pmRNSCompliance with Market Abuse Regulation
14th Mar 20247:00 amRNSStrategic Review
11th Mar 202410:12 amRNSNet Asset Value(s)
4th Mar 20249:55 amRNSNet Asset Value(s)
1st Mar 20244:18 pmRNSTotal Voting Rights
29th Feb 20242:27 pmRNSTransaction in Own Shares
26th Feb 202410:03 amRNSNet Asset Value(s)
19th Feb 202410:21 amRNSNet Asset Value(s)
14th Feb 20244:36 pmRNSTransaction in Own Shares
9th Feb 20244:56 pmRNSNet Asset Value(s)
2nd Feb 20246:03 pmRNSTransaction in Own Shares
2nd Feb 202412:15 pmRNSNet Asset Value(s)
1st Feb 20242:21 pmRNSTotal Voting Rights
29th Jan 202411:53 amRNSNet Asset Value(s)
26th Jan 20245:14 pmRNSTransaction in Own Shares
19th Jan 20245:03 pmRNSNet Asset Value(s)
16th Jan 20244:34 pmRNSTransaction in Own Shares
15th Jan 20244:20 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.